Novel anti-viral therapeutic
AssigneeThe Regents of the University of California
InventorsBert L. Semler, Richard Virgen-Slane, Janet M. Rozovics, Paul D. Gershon
Life of this patent
Estimating the term…
Abstract
Anti-viral therapeutics for use in viral targets having VPg unlinkase activity, including the broad class of picornaviruses, and therapeutic methods directed at suppression of such activity are provided. Such anti-viral therapies for use against human rhinovirus, for example, are particularly desirable as they would lessen both the severity and duration of upper respiratory distress in both normal and asthmatic individuals. Assays and purification protocols for detecting and purifying VPg unlinkase are also provided.
Claims20
An anti-viral therapeutic for viruses having VPg unlinkase activity, comprising:
- a therapeutically effective amount of a VPg unlinkase enzyme suppressor.
A method of treating a viral infection for a virus having VPg unlinkase activity comprising:
- administering a therapeutically effective amount of a VPg unlinkase enzyme suppressor.
An assay for monitoring the release of VPg from genomic RNA generally comprising:
- isolating a virion RNA containing an 35S-labeled VPg;
- producing a 35S-VPg-nonanucleotide substrate;
- entering the 35S-VPg-nonanucleotide into a Tris-Tricine polyacrylamide gel;
- and
- monitoring the cleavage of the labeled VPg from the substrate.
A VPg unlinkase purification protocol comprising:
- providing a VPg unlinkase containing target cell homogenate;
- producing a supernatant form said target cell homogenate;
- and
- sequentially fractionating the supernatant by heparin Sepharose, ssDNA-cellulose, anion exchange, size exclusion, and cation exchange chromatography to produce a substantially homogeneous enzyme preparation.
Dependencies are inferred from the claim text.